MarteeLHensleyMD

Professor, Medicine, Weill Cornell Medical College

Overview of Dr. Hensley

Dr. Martee Hensley is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Duke University School of Medicine and has been in practice 28 years. Dr. Hensley accepts several types of health insurance, listed below. She is one of 494 doctors at Memorial Sloan Kettering Cancer Center and one of 494 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
160 East 53rd Street
New York, NY 10022
Book by Phone+1(225) 372-7685

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1992 - 1995
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1989 - 1992
Duke University School of MedicineClass of 1989

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1990 - 2026
NJ State Medical License 2019 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus Start of enrollment: 2005 Jan 01
Completed
Phase 2
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2003 Dec 01
Completed
Phase 2
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Start of enrollment: 2006 Jan 01
Completed
Phase 2
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 2
Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Start of enrollment: 2006 Oct 01
Completed
Phase 2
Levonorgestrel in Preventing Ovarian Cancer in Patients at High Risk for Ovarian Cancer Start of enrollment: 2008 Mar 10
Completed
Phase 2
Economic Outcomes in Patients With Stage III Ovarian Cancer Receiving Paclitaxel and Cisplatin on Clinical Trial GOG-172
Withdrawn
Not Applicable
Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus Start of enrollment: 2001 Aug 01
Completed
Not Applicable
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer Start of enrollment: 2009 Aug 17
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Start of enrollment: 2009 Nov 01
Terminated
Phase 3
Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Start of enrollment: 2012 Jun 04
Terminated
Phase 3
Join now to see all

Publications & Presentations

PubMed

52 citations
Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Gro...
Martee L. Hensley, Danielle Enserro, Helen Hatcher, Petronella B. Ottevanger, Anders Krarup-Hansen
Journal of Clinical Oncology. 2018-10-05
26 citations
A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group study
Susana M. Campos, William E. Brady, Katherine M. Moxley, Roisin E. O'Cearbhaill, Paula S. Lee
Gynecologic Oncology. 2014-06-01
32 citations
Paclitaxel-Based Chemotherapy in Carcinoma of the Fallopian Tube
Mary L. Gemignani, Martee L. Hensley, Rose S. Cohen, Enapandam Venkatraman, Patricia E. Saigo
Gynecologic Oncology. 2001-01-01

Journal Articles

Efficacy and Tolerability of Trabectedin in Elderly Patients with Sarcoma: Subgroup Analysis from a Phase 3, Randomized Controlled Study of Trabectedin or Dacarbazine ...
A Elias, M Milhem, S Patel, S M Schuetze, M L Hensley, Annals of Oncology

Other

Treatment and prognosis of uterine leiomyosarcoma
Hensley ML, Abu-Rustum NR
http://www.uptodate.com/contents/treatment-and-prognosis-of-uterine-leiomyosarcoma
UpToDate, Wolters Kluwer Health - 2013-04-11

Press Mentions

Why the Health of Your Doctor MattersAugust 5th, 2019
Expert Highlights Genetic Testing, Immunotherapy in Endometrial CancerJanuary 11th, 2018
Trabectedin Offers Third-Line Option in Uterine LeiomyosarcomaMarch 24th, 2016
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois BlueChoice Select
BCBS Illinois PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment